TheraRadar
Data updated: May 26, 2026

CORGARD (nadolol)

Trial Activity: Declining
Cardiovascular Approved 1979-12-10
Jump to: Indications Approvals Trials Competitors Safety Patents

Development Insights

The Hospital for Sick Children conducting 2 trials (67%)
2 indications explored (Focused)
→ infantile hemangioma (2 trials)
→ smoking cessation (1 trials)
3
Indications
--
Phase 3 Trials
46
Years on Market

Details

Status
Discontinued
First Approved
1979-12-10
Routes
ORAL
Dosage Forms
TABLET

Companies

USWM
Active Ingredient: NADOLOL

CORGARD Approval History

1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
285 FDA actions from 1979 to 2023 · 2 indication expansions
Dec 2023 SUPPL
Label · Labeling
FDA Letter Label
Jul 2013 SUPPL
Label · Labeling
FDA Letter Label
Jun 2011 SUPPL
Label · Labeling
FDA Letter Label

What CORGARD Treats

3 FDA approvals

Originally approved for its first indication in 1979 . Covers 3 distinct patient populations.

  • Other (3)
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT01010308 1000014079 Ph 2 completed Nadolol for Proliferating Infantile Hemangiomas
NCT02505971 1000048673 Ph 3 completed Nadolol Versus Propranolol in Children With Infantile Hemangiomas
NCT01825122 results posted INVSC001 Ph 2 completed Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CORGARD FDA Label Details

Track CORGARD with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA018063 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment